Hyderabad: Natco Pharma has announced the appointment of T.C. Mallikarjun as Vice President - QC at Pharma Division, Kothur ...

Indian stock markets opened sharply lower on Thursday following US President Donald Trump’s announcement of a 25 per cent tariff on Indian goods, along with penalties related to purchases of Russian ...

Shares of Indian companies heavily reliant on the US market faced intense selling pressure on Dalal Street on Thursday after ...

Pharmaceutical stocks came under pressure on Thursday, July 31, after US President Donald Trump announced a sweeping 25% ...

Nifty Pharma index declined 1.5 per cent in trade after US President Donald Trump warned to impose a 25 per cent tariff on ...

The group acknowledges limited growth in South Africa’s price-regulated pharma market but believes Natco’s backing will ...

The Nifty Pharma index ended Friday on a positive note, advancing 0.54%. Top gainers included Cipla Ltd and Torrent Pharmaceuticals Ltd, while Natco Pharma Ltd led the losses.

Natco Pharma’s R4-billion proposal to take a stake of almost 36% in Adcock Ingram was a vote of confidence in the JSE-listed ...

The U.S. FDA had inspected the API facility, in Mekaguda here, from June 9-13 and issued Form 483 with one observation. The regulator had classified it as “voluntary action indicated” (VAI), the ...

On Thursday, 1644 stocks advanced, 2409 declined and 168 remained unchanged on Bombay Stock Exchange with advance decline ...

Adcock Ingram surged the most on record after India’s Natco Pharma said it will acquire a stake in the South African drugmaker for about $232 million (R4 billion).

Natco Pharma informed that the U.S. Food and Drug Administration (US FDA) has issued an EIR for its active pharmaceutical ingredient (API) division located in Mekaguda, Hyderabad, Telangana.